Layer 2 · ONTO — Onto Innovation
One-line thesis
Onto Innovation is the bump-inspection / metrology duopoly partner to Camtek, structurally cheaper on forward multiples, and the Rigaku 27% stake announcement plus the Q1 beat and the average sell-side PT of $352 (versus $271 spot) signals a 30% PT upside cushion that Camtek lacks at current levels.
What Onto Innovation physically does
Onto operates across three semiconductor-equipment categories: bump and incoming-wafer inspection (the Dragonfly platform inherited from the 2019 Rudolph Technologies merger), in-die optical and X-ray metrology (the Atlas family of overlay and film-thickness measurement tools, plus the Iris XRD line for film stress and composition), and lithography systems for advanced packaging (the JetStep step-and-flash imprint lithography line for fan-out wafer-level packaging). The portfolio is broader than Camtek's pure HBM bump-inspection focus, with material exposure to fan-out packaging (Apple A-series, AMD chiplets), advanced photoresist metrology at TSMC and Samsung, and the front-end memory-process metrology business at Micron and SK Hynix.
The Dragonfly inspection platform — originally developed by Rudolph Technologies and significantly expanded by Onto post-merger — performs the same physical task as Camtek's Eagle: optical inspection of µbumps, redistribution layers, and incoming wafer surfaces for HBM and advanced-packaging applications. The Atlas in-die metrology family is a different product category — these are precision overlay and film-thickness measurement tools that ship into leading-edge logic and DRAM fabs and sit upstream of the assembly process at the wafer-manufacturing tier. The JetStep step-and-flash imprint lithography platform is a niche but strategically important line — it is the dominant tool for fan-out wafer-level packaging redistribution-layer patterning at OSAT customers (ASE, Amkor, SPIL), which is the packaging platform used for Apple's M-series and A-series chips plus AMD's chiplet products.
For HBM specifically, Onto's Dragonfly platform competes head-on with Camtek's Eagle for bump-inspection share — with Onto more dominant at Micron and Camtek more dominant at SK Hynix as discussed above. The Atlas in-die metrology family is the broader product line that gives Onto exposure beyond HBM into the leading-edge logic and advanced-packaging metrology pull. The customer relationship at Micron has been particularly important — Onto's Boise / Idaho installed base is the principal reason the company's revenue mix has shifted toward memory-equipment exposure over the past three years.
The pending Rigaku partnership (announced May 7 with the 27% stake purchase for $710M) brings Onto a strategic relationship to the leading Japanese X-ray analytical instrument vendor, which adds capability in X-ray fluorescence (XRF) and X-ray diffraction (XRD) for advanced HBM packaging — an emerging metrology need as HBM stack heights move to 16-Hi and 20-Hi. The strategic logic is the same as Camtek developing toward hybrid-bonding metrology: positioning for the next-generation inspection paradigm where traditional optical methods become insufficient. The Rigaku capabilities specifically enable measurement of bonded interfaces, film composition at stacked die boundaries, and stress / strain analysis at the through-silicon-via structure — all of which become materially more important as the µbump shrinks and the inspection demand shifts to direct-bond integrity measurements.
The CPO (co-packaged optics) opportunity layer is the additional adjacency: as Broadcom Bailly, Cisco silicon photonics products, and the broader CPO category ramp through 2027-28, the panel-level packaging inspection requirements for these products fall squarely in Onto's JetStep + Dragonfly product overlap. This is a single-digit revenue contributor currently but is structurally one of the highest-growth adjacency lines in the equipment landscape.
The financial print
Q1 2026 (reported May 7 2026) printed revenue of $291.95M against $289M consensus — modest beat (+1%) — and EPS of $1.42 against $1.37 consensus (+3.6%). Guidance for Q2 was raised to greater than $300M, implying 12-14% core organic growth. The Rigaku 27% stake at $710M was the strategic-narrative headline alongside the print, with the JV expected to close in H2 26 and a $500M bridge-loan added to the balance sheet for the transaction.
The Q1 revenue mix matters for tracking the underlying franchise health. Specialty device and advanced packaging — the HBM bump-inspection and packaging-related book — ran approximately $180-190M (roughly 62-65% of revenue), with the front-end advanced-nodes business at approximately $80-90M and lithography (JetStep) at $20-25M. The packaging book grew approximately 30% YoY while the front-end book was approximately flat — indicating the HBM-driven tailwind is doing the lifting, and the leading-edge logic metrology line is operating at trough utilisation but is positioned for an N2 / 18A ramp inflection through 2027.
The stock at $271 is 1m +15%, 3m +18%. The average sell-side PT of $352 — published as recently as May 13 (Simply Wall St aggregation) — implies 30% upside to spot, the widest cushion of any name in this Tier A list. Q2 prints August 6. Consensus is the guided $300M+ revenue range plus EPS around $1.50-1.60.
The valuation differential versus Camtek is the principal observation: ONTO trades at roughly 28x forward versus Camtek's 33x forward despite broadly comparable HBM exposure. The discount reflects the broader product portfolio (more cyclical drag from non-HBM segments) but is wider than the structural difference justifies given Onto's stronger Micron position. The cushion to consensus PT (30%) is also wider than Camtek (~10%), creating the asymmetric R/R that argues for owning both names paired but with the Onto position carrying the heavier weighting on entry valuation.
Customer mix
Micron is the largest customer at approximately 25-30% of revenue (HBM and DRAM front-end metrology, plus bump-inspection on the Idaho HBM line). TSMC at 15-20% (advanced-packaging metrology, photoresist film-thickness inspection at N3 and N2). SK Hynix at 10-15% (front-end DRAM metrology, with smaller bump-inspection share than Camtek). Samsung at 10-12% (memory and foundry). The remaining 25-30% is split across Apple's OSAT supply chain (fan-out wafer-level packaging at ASE / Amkor), Intel, and the broader specialty foundries.
The customer mix is materially more diversified than Camtek's HBM-concentrated mix, which is the structural reason Onto carries a discount on the bump-inspection franchise but a premium on the broader metrology mix. Net result is a more balanced revenue profile with less HBM-cycle beta.
Competitive context
KLAC is the competitor at the front-end metrology tier — Onto's Atlas competes against KLA's overlay and CD-SEM products at TSMC, Samsung, Intel — and KLA holds the larger share at front-end logic. Camtek is the direct competitor in bump-inspection as discussed above. The structural defence is the multi-product portfolio: where any single competitor wins on one product line, Onto has typically positioned an adjacent product line that wins on another step. The Rigaku partnership extends this strategy into X-ray metrology.
Terminal risk
Same as Camtek on the bump-inspection franchise — hybrid-bonding paradigm shift in HBM5 / HBM6 changes the inspection mix. The mitigant is broader: Onto's broader portfolio (in-die metrology, lithography for advanced packaging, the Rigaku X-ray adjacency) is more diversified and less dependent on the µbump generation than Camtek. The Rigaku JV specifically positions Onto for the next-generation inspection paradigm where X-ray methods become primary.
Secondary terminal risk: the Rigaku partnership integration risk — at $710M stake plus $500M bridge loan, the balance sheet is more levered than Onto's historical conservatism. If the JV underperforms on synergies, the equity multiple compresses.
Bull case
The base case is FY26 revenue of $1.18-1.22B (versus FY25 around $1.05B), FY27 revenue of $1.35-1.45B, gross margin holding 53-55%, and non-GAAP EPS rising from FY26 around $6.20 toward FY27 $7.20-7.80. At 32x forward — premium to current 28x, reflecting the Rigaku synergy and HBM compounding — that prints the stock at $230-250 in 2027, broadly flat to spot but with capital return underpinning.
The upside case is the Rigaku JV delivering on synergy ahead of schedule and the HBM bump-inspection share at Micron expanding into the Idaho IPF2 ramp through 2027 — combined that lifts FY27 EPS toward $9.00 and the stock at $310-340 in 2027, +14-25% from spot, consistent with the sell-side $352 average PT.
The CPO panel-level packaging inspection adjacency is the upside-case leg most under-appreciated by current sell-side modelling. As Broadcom Bailly 51.2T CPO products ramp in 2027, as Cisco silicon photonics deployments scale at hyperscaler data centers, and as the broader CPO category transitions from pilot to production volume through 2028, the panel-level packaging metrology and inspection requirements scale proportionally. Onto's JetStep imprint lithography platform plus the Dragonfly inspection platform are positioned to capture roughly 60-70% of this addressable inspection TAM. Even at the lower end of CPO adoption assumptions, this is a $200-400M annual revenue line by 2028 — material at Onto's $1.2B revenue base.
The Rigaku synergy case is the second under-appreciated leg. The X-ray metrology capability that Rigaku brings is uniquely positioned for the HBM stacked-die inspection market, where traditional optical inspection methods reach physical limits as bond pitches shrink below 10 microns. If the JV delivers commercial integration ahead of schedule and Onto-Rigaku captures the X-ray-based stack-integrity inspection volume that the HBM4 16-Hi generation requires, the synergy line accretes meaningfully through 2027.
Gap / bear case
Three concerns. First, the Rigaku integration. The $710M stake + $500M bridge loan adds meaningful balance-sheet complexity to a company that has historically run net cash; if the synergies disappoint, the equity multiple compresses 100-200bp. Second, the front-end metrology business carries cyclical exposure to broader logic and DRAM capex — if 2027 sees a memory cycle softening, Onto's revenue takes a haircut alongside KLAC and LRCX. Third, the +18% three-month rally has compressed the entry-level discount versus consensus PT — but the cushion is still wider than peers, which is the principal R/R argument.
Optionality
Three options. Rigaku JV synergy realization through H2 26 / 2027 — every dollar of incremental X-ray metrology revenue at the HBM packaging tier accretes directly to Onto. The CPO (co-packaged optics) panel-level packaging inspection market — emerging in 2027 as Broadcom Bailly and Cisco silicon photonics products ramp, this is a $500M+ inspection TAM addressed by Onto's JetStep + Dragonfly portfolio. And the more speculative option: M&A from a larger equipment vendor (AMAT, LRCX, KLAC) consolidating the bump-inspection duopoly — neither base case nor near-term, but the strategic logic exists.
The trade
ONTO — BUY 8/10. Entry: $270-275 spot; better entry on $250-260 pullback. Position size: 1.5-2.5% of NLV, paired with CAMT at 3-4% combined for the bump-inspection duopoly trade. Stop: daily close below $215 (the December 2025 base and prior breakdown level). Catalyst date: August 6 Q2 print; Rigaku JV close target H2 26; Micron Q3 print June 25 (read-through on Boise HBM capex); SEMICON West July 2026 commentary. Trim/exit triggers: Rigaku JV synergy timeline slipping into 2027; front-end metrology revenue softening below 5% YoY; any verifiable share loss at Micron bump-inspection to Camtek. Conviction: the cheaper of the bump-inspection duopoly with a Rigaku option leg on top. Treat as the value half of the pair-trade with CAMT — ONTO has more upside on PT cushion, CAMT has cleaner HBM-pure-play exposure.